Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment

Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment Brian L. Abbott Oncologist 2006; 11: 21-30 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in acute and chronic leukemias and multiple myeloma and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss prognostic markers for CLL, including ZAP70 expression, IgVH rearrangements, and CD38 expression. Describe the latest chemotherapy regimens for CLL, including combinations containing nucleoside analogues and monoclonal antibodies. Describe appropriate indications for initiation of treatment for CLL. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 09, 2006 Most Recent Review: May 8, 2007* Most Recent Update: Jan. 09, 2006 Date Credit Expires: Jan. 09, 2008 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.